congresses-banner

The content contained is subject

PublicationView

Oral
T-DXd
SGO 2024 | March 16-18, 2024
Other/Multi
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study
Vicky Makker
Oral
R-DXd
SGO 2024 | March 16-18, 2024
Other/Multi
Raludotatug deruxtecan (R-DXd) monotherapy in patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase 1 study
Kathleen Moore

footer